Previous 10 | Next 10 |
IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2019 Earnings Conference Call March 12, 2020, 08:00 ET Company Participants Thomas Bures - Principal Financial & Accounting Officer & Treasurer Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Head, Translationa...
Pieris Pharmaceuticals (NASDAQ: PIRS ): FY GAAP EPS of -$0.56 beats by $0.20 . Revenue of $46.28M (+59.0% Y/Y) beats by $17.18M . Press Release More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT BOSTON, MA / ACCESSWIRE / March 12, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ...
BOSTON, MA / ACCESSWIRE / February 25, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today an...
Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP ) +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...
These 4 Penny Stocks On Robinhood Are Anticipating Biotechnology Results This Week The idea of buying penny stocks tends to hit certain nerves with certain people. On one hand, you have your open-minded traders who are all about making money. Penny stocks , blue-chip stocks , options, etc....
BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today ...
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2019 Results Earnings Conference Call November 11, 2019, 08:00 AM ET Company Participants Thomas Bures - Principal Financial & Accounting Officer and Treasurer 2 Stephen Yoder - CEO, President Ingmar Bruns - VP, Clinical Development Sh...
Pieris Pharmaceuticals ( PIRS ) Q3 results : Revenues: $15.1M (+81.9%). More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...